高剂量率腔内近距离放疗联合中央屏蔽调强放疗治疗宫颈癌的疗效观察。
Treatment Outcome of the Combination Therapy of High-dose rate Intracavitary Brachytherapy and Intensity-modulated Radiation Therapy With Central-shielding for Cervical Cancer.
机构信息
Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan.
出版信息
In Vivo. 2020 Nov-Dec;34(6):3387-3398. doi: 10.21873/invivo.12177.
BACKGROUND/AIM: This study aimed to evaluate the clinical outcome of intensity-modulated radiation therapy (IMRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT) in uterine cervical cancer (UCC). IMRT consisted of whole-pelvic radiation therapy (WPRT) and sequential WPRT with central-shielding (WPRT-CS).
PATIENTS AND METHODS
Thirty UCC patients treated with IMRT using TomoTherapy, were retrospectively analyzed.
RESULTS
The median dose of WPRT and WPRT-CS was 36 and 14.4 Gy and the median total dose of these was 50 Gy in 25 fractions (Fr). Median HDR-ICBT dose/Fr to Point A was 25 Gy/5 Fr. Median 2 Gy per fraction-equivalent dose (EQD2) of combined WPRT and HDR-ICBT to Point A (α/β=10) was 71.0 Gy. The 3-year local control, disease-free survival, and overall survival rates were 89.9%, 83.3%, and 86.3%.
CONCLUSION
IMRT of WPRT and WPRT-CS given in combination with HDR-ICBT was a feasible therapy resulting in good disease control and tolerance in patients with UCC.
背景/目的：本研究旨在评估调强放疗（IMRT）联合高剂量率腔内近距离放疗（HDR-ICBT）治疗子宫颈癌（UCC）的临床疗效。IMRT 包括全盆腔放疗（WPRT）和中央屏蔽的序贯 WPRT（WPRT-CS）。
患者和方法
回顾性分析了 30 例接受 TomoTherapy 调强放疗的 UCC 患者。
结果
WPRT 和 WPRT-CS 的中位剂量分别为 36 和 14.4 Gy，这些剂量的总中位剂量为 50 Gy，共 25 个分数（Fr）。A 点 HDR-ICBT 的中位剂量/Fr 为 25 Gy/5 Fr。联合 WPRT 和 HDR-ICBT 至 A 点的 2 Gy 等分剂量（EQD2）（α/β=10）中位值为 71.0 Gy。3 年局部控制、无病生存率和总生存率分别为 89.9%、83.3%和 86.3%。
结论
WPRT 和 WPRT-CS 的 IMRT 联合 HDR-ICBT 是一种可行的治疗方法，可使 UCC 患者获得良好的疾病控制和耐受性。
Zotero 插件